Lafayette Clinical Research Group Initiates the Reconnect Trial for Women with HSDD!
Female sexual dysfunction affects as many as 40% of premenopausal women during their lifetime. In many instances, the symptoms of sexual dysfunction affect relationships and bring stress/distressful feelings that complicate the ability to resolve the problem. Approximately 2-million women are affected, yet they find it difficult to communicate the problem to their primary care physician or gynecologist. Sadly, even when suggesting the problem to their physician, few options are shared as there are seemingly no effective treatments. This is something that may be changing.
The Reconnect Trial is a randomized trial that is evaluating bremelanotide. This is an injectable agent originally studied for sunless tanning. Bremelanotide is a peptide or protein that acts in the brain to help resolve symptoms of female sexual dysfunction associated with HSDD. We will be updating messages and new information about the Reconnect Study, yet you may learn more by visiting www.reconnectstudy.com, calling Teresa at Lafayette Clinical Research Group at (765) 269-7134, or emailing [email protected]